Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg said its sources preferred […]
Dexcom
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions […]
CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]
Dexcom study shows strong accuracy for next-gen G7 CGM in pediatric T1D patients
Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children. San Diego-based Dexcom’s study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review. […]
Dexcom dips after hours on Q1 EPS miss, remains confident of U.S. G7 launch this year
Dexcom (Nasdaq:DXCM) shares took a hit after hours today on first-quarter results that fell short of the consensus earnings forecast. DXCM shares were down 6.2% after hours but mostly recovered by the end of the next day. The San Diego-based company posted profits of $97.3 million, or 93¢ per share, on sales of $628.8 million […]
Welldoc says CGM, digital health platform combination provides better glycemic outcomes
Welldoc said that its combination of real-time continuous glucose monitoring (CGM) and digital health impacts glucose control in type 2 diabetes. Columbia, Maryland-based Welldoc presented data at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from a study of real-time CGM and digital health in individuals with type 2 diabetes not treated with […]
Dexcom announces availability of G6 for Tricare members as formulary pharmacy benefit
Dexcom (Nasdaq:DXCM) announced that its G6 continuous glucose monitoring (CGM) system will be available through Tricare. San Diego-based Dexcom’s CGM will be more easily available to military members, their families and retirees with diabetes as a Tricare brand-name formulary pharmacy benefit. According to a news release, effective mid-April 2022, members with diabetes will be eligible […]
Dexcom launches Dexcom One CGM in the UK
Dexcom (NSDQ:DXCM) announced today that it launched the new Dexcom One continuous glucose monitoring (CGM) system in the United Kingdom. San Diego-based Dexcom designed the Dexcom One system as an easy-to-use, real-time CGM (rt-CGM) that it aims to make more affordable and accessible for people with diabetes in the UK. According to a news release, […]
Analysts say high payor coverage, increased CGM adoption bodes well for Abbott, Dexcom
Analysts have suggested that companies like Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) may benefit from expected reimbursement progress. BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen. The two experts offered insights into prescriber and patient interest in […]
Dexcom’s board approves 4-for-1 forward stock split
Dexcom (Nasdaq:DXCM) announced today that its board of directors approved a four-for-one forward split of the company’s common stock. San Diego-based Dexcom’s stock split remains contingent upon stockholder approval of a restated certificate of incorporation. Approval of that would increase the number of authorized shares of common stock from 200 million to 800 million. According […]
